Accessibility Menu
Percheron Therapeutics logo

Percheron Therapeutics(OTC) ATHJF

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-95%
5 Year-98%
1 Year-40%
1 Month-15%
N/A
Percheron Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-27
Percheron Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.04%USD 0.002026-06-25
1 month-15.04%USD 0.002026-06-25
3 month-52%USD 0.012025-12-22
Year to date-52%USD 0.012025-12-22
1 year-40%USD 0.002025-03-31
3 year-95.2%USD 0.052023-07-05
5 year-98.4%USD 0.152021-07-22
Since inception-95.2%USD 0.052007-10-22

Percheron Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$4.55M

Net Income (TTM)

-A$23.30M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 29, 2024

ATHJF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Percheron Therapeutics

Antisense Therapeutics Limited is an Australian biotechnology company focused on developing innovative antisense pharmaceuticals. The company is advancing two primary drug candidates, ATL1102 and ATL1103, targeting various inflammatory conditions and excessive growth hormone activity.

Products and Services
  • ATL1102: An antisense inhibitor in Phase II trials for multiple sclerosis and other inflammatory conditions
  • ATL1103: A second-generation antisense medication targeting growth hormone receptor expression
  • Research and development of additional antisense therapies for unmet medical needs
Growth Outlook
  • Recent Phase II trials for ATL1102 show promising results in treating multiple sclerosis
  • ATL1103 has completed Phase II trials, indicating potential for market entry
  • Strong pipeline positions the company for future growth in the biotechnology sector
Financial Highlights
  • Latest quarterly revenue of AUD 1.77 million reflects a significant increase from previous quarters
  • Cash and cash equivalents stood at AUD 11.87 million as of June 30, 2024
  • Operating expenses for the latest quarter were AUD 8.89 million, indicating ongoing investment in R&D
Antisense Therapeutics Limited is strategically positioned within the biotechnology industry, focusing on antisense technology to address significant medical challenges. The company's commitment to research and development is evident in its ongoing clinical trials and the advancement of its drug candidates. With a solid financial foundation and a promising growth outlook, Antisense Therapeutics Limited represents an intriguing opportunity for investors interested in the biotechnology sector. The recent increase in revenue and substantial cash reserves provide a strong basis for continued development and potential market success.
AI Generated • Jul 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

4

CEO

James Stuart Garner, PhD, MBA

Website

www.PercheronTx.com

Headquarters

Toorak, VIC 3142, AU

ATHJF Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

-125.84%

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

A$4.45M

Operating Income

-A$23.65M

EBITDA

-A$23.27M

Operating Cash Flow

-A$18.36M

Capital Expenditure

-A$32.90K

Free Cash Flow

-A$18.39M

Cash & ST Invst.

A$11.87M

Total Debt

A$39.87K

Percheron Therapeutics Performance Analysis

Percheron Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
Percheron Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-12-30-67.5%
Q42023-06-30120.2%
Q22023-12-3010.5%
Q42024-06-3047.3%
Percheron Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.01N/A
20232023-06-30AUD -0.0170.8%
20242024-06-30AUD -0.01-22.5%
20252025-06-30AUD -0.017.0%
Percheron Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-12-30-85.7%
Q42023-06-30-17.9%
Q22023-12-3028.3%
Q42024-06-30-6.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

A$1.77M

+16.5%

Gross Profit

A$1.75M

+17.0%

Gross Margin

98.92%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

-A$7.18M

-153.6%

EBITDA

-A$7.17M

-151.1%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

A$11.87M

-38.3%

Total Debt

A$39.87K

-82.5%

Accounts Receivable

A$2.51M

+36.3%

Inventory

A$0.00

-100.0%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$39.87K

-57.6%

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-A$5.37M

-27.1%

Operating Cash Flow

-A$5.37M

-27.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OCELOrganicell Regenerative Medicine, Inc.
$2.74-0.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$125.07+0.09%
TTDThe Trade Desk
$14.16-0.20%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.50+0.02%
INTCIntel
$99.69-0.00%

Questions About ATHJF

What is the current price of Percheron Therapeutics?

Percheron Therapeutics is trading at N/A per share.

What is the 52-week range for Percheron Therapeutics?

Over the past 52 weeks, Percheron Therapeutics has traded between N/A and N/A.

How much debt does Percheron Therapeutics have?

As of the most recent reporting period, Percheron Therapeutics reported total debt of A$16.95K.

How much cash does Percheron Therapeutics have on hand?

Percheron Therapeutics reported A$404.91K in cash and cash equivalents in its most recent financial results.

What is Percheron Therapeutics’s dividend yield?

Percheron Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services